CF PharmTech (HKG:2652) said it expects 2 million yuan to 3 million yuan in attributable profit for 2025, down from 21.1 million yuan in 2024, according to a Hong Kong bourse filing Friday.
Shares of the pharmaceutical firm fell nearly 2% in late morning trade Monday.
The drop in profit comes amid an expected decline in revenue to 410 million yuan to 450 million yuan from 607.8 million yuan in 2024.
The company's financial results are due by the end of March.